https://en.bulios.com/ticker/ATHE
Alterity Therapeutics Limited (ATHE) Stock | ATHE Stock Price & Analysis - Bulios
Get the latest news and market analysis for Alterity Therapeutics Limited (ATHE). Stay up-to-date on ATHE Stock price and share price with Bulios. Explore our...
alterity therapeuticsstock pricelimitedatheanalysis
https://markets.businessinsider.com/news/stocks/alterity-therapeutics-raises-a-40m-in-placement-1034335017
Alterity Therapeutics raises A$40M in placement | Markets Insider
Alterity Therapeutics (ATHE) has received binding commitments for a capital raising of A$40M via a two tranche placement of fully paid ordinary ...
alterity therapeuticsmarkets insiderplacement
https://catalystalert.io/company/ATHE
ATHE Drug Pipeline & Catalysts | ALTERITY THERAPEUTICS LTD | CatalystAlert | CatalystAlert
Track ALTERITY THERAPEUTICS LTD (ATHE) drug pipeline and upcoming FDA catalysts. View Phase 3 trials, PDUFA dates, and clinical trial results.
drug pipelinealterity therapeuticsathecatalystsltd
https://biotechdispatch.com.au/news/alterity-therapeutics-announces-positive-trial-results-in-multiple-system-atrophy
Alterity Therapeutics announces positive trial results in Multiple System Atrophy - Biotech
Alterity Therapeutics (ASX:ATH) has announced positive topline results from the ATH434-201 randomised, double-blind, placebo-controlled Phase 2 clinical trial...
multiple system atrophyalterity therapeuticstrial resultsannouncespositive
https://www.kappasignal.com/2026/02/alterity-therapeutics-stock-forecast.html
Alterity Therapeutics Stock Forecast
KappaSignal is a leading financial technology firm specializing in AI-driven stock analysis and forecasting.
alterity therapeuticsstock forecast
https://www.finanznachrichten.de/nachrichten-2026-04/68228599-alterity-therapeutics-limited-alterity-therapeutics-appoints-highly-experienced-biotech-executive-ann-cunningham-to-its-board-of-directors-399.htm
ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Appoints Highly Experienced Biotech Executive...
MELBOURNE, Australia and SAN FRANCISCO, April 17, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a...
alterity therapeuticshighly experiencedlimitedbiotechexecutive
https://www.biospace.com/alterity-therapeutics-announces-first-regulatory-authorization-to-proceed-with-ath434-phase-2-clinical-trial
Alterity Therapeutics Announces First Regulatory Authorization to Proceed with ATH434 Phase 2...
Dec 14, 2021 - Alterity Therapeutics today announced that the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) has authorized Alterity's Phase 2 clinical...
alterity therapeuticsannouncesfirstregulatoryauthorization
https://pharmadispatch.com/news/alterity-therapeutics-completes-last-patient-pisit-in-ath434-201-trial-in-multiple-system-atroph
Alterity Therapeutics completes last patient visit in ATH434-201 trial in multiple system atrophy -...
Alterity Therapeutics (ASX:ATH) has announced that the last patient in its ATH434-201 Phase 2 trial in early-stage multiple system atrophy has completed the...
multiple system atrophyalterity therapeuticspatient visitcompleteslast
https://alteritytx.com/
Alterity Therapeutics
alterity therapeutics
https://asiapacificnewsnetwork.com/article/911074235-alterity-therapeutics-to-deliver-presentations-at-multiple-medical-conferences-in-may-2026
Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026 | Asia...
Asia Pacific News Network is an online news publication focusing on the Asia Pacific: Following the news from Asia and the Pacific
alterity therapeuticsmedical conferencesin maydeliverpresentations
https://pro.kraken.com/app/trade/stocks-athe
ATHE (Alterity Therapeutics) - Trade Stocks | Kraken Pro
Trade Alterity Therapeutics (ATHE) on Kraken Pro. Trade stocks alongside crypto with real-time pricing, professional execution, and multi-asset portfolio...
alterity therapeuticstrade stockskraken proathe